Investing.com - NuCana reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
NuCana announced earnings per share of £-0.0007 on revenue of £0.00. Analysts polled by Investing.com anticipated EPS of £-0.0012 on revenue of £0.00.
NuCana shares are down 3.08% from the beginning of the year, still down 51.20% from its 52 week high of £3.32 set on February 8. They are outperforming the Nasdaq which is down 17.3% from the start of the year.
NuCana follows other major Healthcare sector earnings this month
NuCana's report follows an earnings missed by Eli Lilly on August 4, who reported EPS of £1.25 on revenue of £6.49B, compared to forecasts EPS of £1.7 on revenue of £6.85B.
Pfizer had beat expectations on July 28 with second quarter EPS of £2.04 on revenue of £27.74B, compared to forecast for EPS of £1.72 on revenue of £25.49B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar